Selective estrogen receptor modulation in pancreatic β-cells and the prevention of type 2 diabetes

Islets

Volumn 4, Issue 2, 2012, Pages 173-176

  Tiano, Joseph P ^a   Mauvais Jarvis, Franck ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cell; Estrogen receptor; Islet; Lipogenesis; Type 2 diabetes

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FATTY ACID SYNTHASE; G PROTEIN COUPLED RECEPTOR 30; RALOXIFENE; STAT3 PROTEIN; TRIACYLGLYCEROL;

ANIMAL CELL; ARTICLE; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; FEMALE; HUMAN; HUMAN CELL; LIPOGENESIS; LIPOTOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; POSTMENOPAUSE; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; DIABETES MELLITUS, TYPE 2; FEMALE; INSULIN-SECRETING CELLS; MICE; RALOXIFENE; RECEPTORS, ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; STAT3 TRANSCRIPTION FACTOR; TRIGLYCERIDES;

EID: 84862219400     PISSN: 19382014     EISSN: 19382022     Source Type: Journal    
DOI: 10.4161/isl.19747     Document Type: Article

References (21)

1. Liu S, Mauvais-Jarvis F. Minireview: Estrogenic protection of beta-cell failure in metabolic diseases. Endocrinology 2010; 151:859-64; PMID:19966178; http://dx.doi.org/10.1210/en.2009-1107.
2. Mauvais-Jarvis F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol Metab 2011; 22:24-33; PMID:21109497; http://dx.doi.org/10.1016/j.tem.2010.10. 002.
3. Tiano JP, Mauvais-Jarvis F. Importance of oestrogen receptors to preserve functional beta-cell mass in diabetes. Nat Rev Endocrinol 2012.
4. Tiano JP, Delghingaro-Augusto V, Le May C, Liu S, Kaw MK, Khuder SS, et al. Estrogen receptor activation reduces lipid synthesis in pancreatic islets and prevents β cell failure in rodent models of type 2 diabetes. J Clin Invest 2011; 121:3331-42; PMID:21747171; http://dx.doi.org/10.1172/JCI44564.
5. Le May C, Chu K, Hu M, Ortega CS, Simpson ER, Korach KS, et al. Estrogens protect pancreatic beta-cells from apoptosis and prevent insulin-deficient diabetes mellitus in mice. Proc Natl Acad Sci USA 2006; 103:9232-7; PMID:16754860; http://dx.doi.org/10.1073/pnas.0602956103.
6. Liu S, Le May C, Wong WP, Ward RD, Clegg DJ, Marcelli M, et al. Importance of extranuclear estrogen receptor-alpha and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes 2009; 58:2292-302; PMID:19587358; http://dx.doi.org/10.2337/db09-0257.
7. Wong WP, Tiano JP, Liu S, Hewitt SC, Le May C, Dalle S, et al. Extranuclear estrogen receptor alpha stimulates NeuroD1 binding to the insulin promoter and favors insulin synthesis. Proc Natl Acad Sci USA 2010; 107:13057-62; PMID:20616010; http://dx.doi.org/10.1073/pnas.0914501107.
8. Inoue H, Ogawa W, Ozaki M, Haga S, Matsumoto M, Furukawa K, et al. Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 2004; 10:168-74; PMID:14716305; http://dx.doi.org/ 10.1038/nm980.
9. Ueki K, Kondo T, Tseng YH, Kahn CR. Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 2004; 101:10422-7; PMID:15240880; http://dx.doi.org/10.1073/pnas.0402511101.
10. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al.; Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321-33; PMID:12117397; http://dx.doi.org/10.1001/jama.288. 3.321.
11. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003; 348:618-29; PMID:12584371; http://dx.doi.org/10.1056/NEJMra022219.
12. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al.; Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999; 282:637-45; PMID:10517716; http://dx.doi.org/10.1001/jama.282.7.637.
13. Fuchs-Young R, Glasebrook AL, Short LL, Draper MW, Rippy MK, Cole HW, et al. Raloxifene is a tissue-selective agonist/antagonist that functions through the estrogen receptor. Ann NY Acad Sci 1995; 761:355-60; PMID:7625735; http://dx.doi.org/10.1111/j.1749-6632.1995.tb31392.x.
14. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641-7; PMID:9385122; http://dx.doi.org/10.1056/NEJM199712043372301.
15. Hozumi Y, Kawano M, Jordan VC. In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen. Eur J Endocrinol 2000; 143:427-30; PMID:11022187; http://dx.doi.org/10.1530/eje.0.1430427.
16. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279:1445-51; PMID:9600478; http://dx.doi.org/ 10.1001/jama.279.18.1445.
17. Cagnacci A, Paoletti AM, Zanni A, Arangino S, Ibba G, Orrù M, et al. Raloxifene does not modify insulin sensitivity and glucose metabolism in postmenopausal women. J Clin Endocrinol Metab 2002; 87:4117-21; PMID:12213858; http://dx.doi.org/10.1210/jc.2002-020120.
18. Lasco A, Gaudio A, Morabito N, Previti M, Mileto A, Frisina N, et al. Effects of a long-term treatment with raloxifene on insulin sensitivity in postmenopausal women. Diabetologia 2004; 47:571-4; PMID:14762655; http://dx.doi.org/10.1007/s00125-004-1328-4.
19. Carr MC, Knopp RH, Brunzell JD, Wheeler BS, Zhu X, Lakshmanan M, et al. Effect of raloxifene on serum triglycerides in women with a history of hypertriglyceridemia while on oral estrogen therapy. Diabetes Care 2005; 28:1555-61; PMID:15983300; http://dx.doi.org/10.2337/diacare.28.7.1555.
20. Matsumura M, Tashiro K, Miura A, Tajima T, Kinoshita I, Kojima E, et al. A case of non-alcoholic fatty liver disease (NAFLD) aggravated after treatment with raloxifene. Nihon Shokakibyo Gakkai Zasshi 2011; 108:2036-41; PMID:22139492.
21. Barrett-Connor E, Ensrud KE, Harper K, Mason TM, Sashegyi A, Krueger KA, et al. Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 2003; 25:919-30; PMID:12852708; http://dx.doi.org/10.1016/S0149-2918(03)80114-5.